DUBAI – Vector Pharma FZCO has entered into an exclusive distribution agreement with Ascendis Pharma (NASDAQ:ASND) A/S to bring two treatments for rare diseases to the Gulf Cooperation Council (GCC) countries. This partnership will allow Vector to distribute Skytrofa™ and Yorvipath™ for pediatric growth hormone deficiency and adult hypoparathyroidism, respectively.
Under the agreement, Vector Pharma will leverage its sales and marketing capabilities to provide these therapies to patients across Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain. Skytrofa, approved by the FDA and the European Commission, is a once-weekly treatment for children and adolescents with growth hormone deficiency. Yorvipath is approved by the European Commission as a parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism.
Patrick Jordan, Managing Partner of Vector Pharma, expressed enthusiasm about the agreement, emphasizing the significance of introducing TransCon technology-based therapeutics to the GCC region. These treatments are expected to serve as valuable resources for endocrinologists and healthcare providers treating these conditions.
Camilla Harder Hartvig, Executive Vice President and Chief Commercial Officer at Ascendis Pharma, also commented on the partnership, highlighting Vector Pharma's experience in the region and their ability to effectively engage with patients, payers, and providers.
Vector Pharma, established in 2019, aims to be a leading distributor for rare diseases, oncology, and specialized therapeutics in the Middle East, North Africa, and Turkish markets
Ascendis Pharma is committed to using its TransCon technology to develop therapies that significantly improve patient lives.
This article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.